

FIVE PRIME THERAPEUTICS INC

Form 8-K

November 14, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 13, 2014**

**Five Prime Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction**

**of incorporation)**

**001-36070  
(Commission**

**File Number)**

**26-0038620  
(I.R.S. Employer**

**Identification No.)**

**Two Corporate Drive**

**94080**

**South San Francisco, California**  
**(Address of principal executive offices)** **(Zip Code)**  
**Registrant's telephone number, including area code: (415) 365-5600**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Definitive Material Agreement**

On November 13, 2014, Five Prime Therapeutics, Inc. ( FivePrime ) and Britannia Biotech Gateway Limited Partnership (the Landlord ) entered into the First Amendment to Lease (the Amendment ), effective November 13, 2014, which amends certain terms of the Lease, dated March 22, 2010, between FivePrime and the Landlord (the Lease ) regarding FivePrime s lease of office and laboratory space located at Two Corporate Drive, South San Francisco, California. The Amendment increases the amount of space leased by FivePrime under the Lease by 11,743 square feet (the Expansion Premises ), from 69,492 square feet to 81,235 square feet, all of which is located in a single building at Two Corporate Drive, South San Francisco, California. FivePrime expects to begin occupying the Expansion Premises on January 1, 2015 and begin paying rent for the Expansion Premises on May 1, 2015 (the Rent Start Date ), subject in each case to extension to the extent the existing tenant of the Expansion Premises fails to fully surrender and vacate the Expansion Premises by January 1, 2015. Subject to the terms of the Lease, FivePrime s lease of the Expansion Premises will expire on December 31, 2017, which is coterminous with the expiration of FivePrime s lease of the existing premises under the Lease. FivePrime will pay the Landlord minimum monthly rent with respect to the Expansion Premises as set forth in the table below:

<b>Period</b>		<b>Minimum Monthly Rent For Expansion Premises</b>	<b>Monthly Rent per Square Foot for Expansion Premises</b>
Rent Start Date	December 31, 2015	\$ 39,339.05	\$ 3.35
January 1, 2016	December 31, 2016	\$ 40,513.35	\$ 3.45
January 1, 2017	December 31, 2017	\$ 41,687.65	\$ 3.55

FivePrime is entitled to a one-time improvement allowance of \$211,374 from the Landlord for costs relating to the design and construction of improvements to the Expansion Premises subject to the terms and conditions of a work letter attached to the Amendment.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed herewith as Exhibit 10.1.

**Item 9.01 Financial Statements and Exhibits.****(d) Exhibits.**

Exhibit No.	Description
10.1	First Amendment to Lease, effective as of November 13, 2014, by and between the registrant and Britannia Biotech Gateway Limited Partnership

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Five Prime Therapeutics, Inc.**

By: /s/ Francis Sarena  
Francis Sarena  
Senior Vice President, General Counsel &  
Secretary

Dated: November 14, 2014

**EXHIBIT INDEX**

Exhibit No.	Description
10.1	First Amendment to Lease, effective as of November 13, 2014, by and between the registrant and Britannia Biotech Gateway Limited Partnership